AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Aldeyra Therapeutics Inc. (ALDX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.74

-0.04 (-0.59%)

At close: Feb 20, 2025, 3:59 PM

6.72

-0.30%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	6.69
Market Cap	401.36M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.75
PE Ratio (ttm)	-8.99
Forward PE	n/a
Analyst	Buy

Ask	6.85
Volume	228,527
Avg. Volume (20D)	391,877
Open	6.78
Previous Close	6.78
Day's Range	6.58 - 6.81
52-Week Range	2.71 - 6.92
Beta	undefined

About ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical tria...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 2, 2014

Employees 9

Stock Exchange NASDAQ

Ticker Symbol ALDX

Website https://www.aldeyra.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for ALDX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 48.37% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 months ago

+11.64%

Aldeyra Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

6 months ago

+28.53%

Aldeyra Therapeutics shares are trading higher after the company achieved the primary endpoint in its Phase 3 trial for Reproxalap ophthalmic solution in treating dry eye disease. The company anticipates resubmitting its NDA in 2024.

News

1 month ago · seekingalpha.com

Aldeyra Therapeutics: Key Inflection Point Ahead

Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Drug giant AbbVie has a significant option agreement on Aldeyra's primary pipeline asse...

2 months ago · zacks.com

Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?

Investors need to pay close attention to Aldeyra Therapeutics (ALDX) stock based on the movements in the options market lately.

2 months ago · businesswire.com

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...